The advent of monoclonal antibodies to Tumor necrosis factor-α (TNF), has revolutionized the treatment in rheumatoid arthritis (RA). These agents have proved to be highly efficacious, making remission an achievable goal in RA. Golimumab is a human monoclonal antibody to TNF, which is approved by the US FDA for the treatment of RA, psoriatic arthritis and ankylosing spondylitis since April 2009. Golimumab is a useful addition to the therapeutic armamentarium against rheumatoid arthritis. It has proven efficacy in RA patients with active disease, despite treatment with methotrexate and also found to be useful in patients who have failed on a prior anti-TNF agent. It offers a reasonable alternative to other anti-TNF drugs like infliximab, adalimumab or etanercept. The short-term safety profile, based on short-term RCTs, is reasonable with no differences in total adverse events, serious infections, cancer, tuberculosis or deaths. However, Long-term surveillance studies are needed for safety assessment.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I consider that working with you has been the most interesting and friendly process I have experienced publishing. The staff have been very supportive to me, quickly addressing every concern I had. The whole process from the arrival of manuscript to the publication is the fastest I´ve ever experienced, and is very convenient for authors. The staff kept us informed about the whole rigorous process step by step which is a great advantage ...